Submitted: 20 Feb 2023
Accepted: 05 May 2023
ePublished: 01 Jun 2023
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

J Nephropharmacol. 2023;12(2): e10589.
doi: 10.34172/npj.2023.10589

Scopus ID: 85162132129
  Abstract View: 1171
  PDF Download: 526

Clinical Trial

The effect of adding ivermectin to the standard COVID-19 treatment in intubated patients

Reza Baghbanian 1 ORCID logo, Mohsen Savaie 2* ORCID logo, Farhad Soltani 2 ORCID logo, Mahbobeh Rashidi 2 ORCID logo, Mehrdad Dargahi MalAmir 3 ORCID logo, Fereshteh Amiri 2 ORCID logo, Nima Bakhtiari 2 ORCID logo

1 Department of Anesthesiology and Critical Care, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
2 Pain Research Center, Imam Khomeini Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
3 Department of Pulmonology, Air Pollution and Respiratory Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
*Corresponding Author: Mohsen Savaie, Email: drsavaie@gmail.com, , Email: Savaie-m@ajums.ac.ir


Introduction: Effective antiviral medications with minimal side effects has received scholarly attention since the start of the COVID-19 pandemic. Ivermectin, a long-time anti-parasitic drug, has been proven through laboratory tests to have anti-COVID-19 effects.

Objectives: This study investigated the effects of inclusion of ivermectin to the standard treatment of mechanically ventilated patients.

Patients and Methods: This study is a double-blinded, randomized, placebo-controlled clinical trial that was conducted on COVID-19 patients, in Ahvaz, Iran, from March 2020 to September 2021. Intubated COVID-19 patients who met the inclusion criteria were randomly allocated into two groups, placebo (n = 29) and the ivermectin-treated (n = 31). The primary outcome was the mortality, and the secondary outcomes were pulmonary compliance and vital signs.

Results: Two groups were similar regarding demographic characteristics such as age, gender, the length of time since the onset of symptoms before intubation, the level of lactate dehydrogenase (LDH) in the blood. Moreover, the difference in erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), D-dimer, and interleukin 6 (IL-6) was not significant between the two groups. Regarding mortality rate, no significant difference between the two groups was detected. Furthermore, O2 saturation on day 5 was significantly higher in the ivermectin group as opposed to the control group (P=0.008). No statistically significant difference was found between the two groups regarding respiratory rate, heart rate, systolic and diastolic blood pressure, and lung compliance (dynamic and static).

Conclusion: Regarding the importance of blood oxygen saturation in COVID-19 patients, our results showed no significant effect of ivermectin in the treatment of ventilated COVID-19 patients, suggesting that its addition to the standard COVID-19 treatment either is ineffective or has no synergistic effect.

Trial Registration: The trial protocol was approved by the Iranian Registry of Clinical Trials (Identifier: IRCT20190417043295N2; https://www.irct.ir/trial/57603, ethical code#IR.AJUMS. REC.1400.234).

Implication for health policy/practice/research/medical education:

Various drugs, alone or in combination with other treatments, have been tested to find an effective treatment for COVID-19. This study investigated the effectiveness of one of these drugs (i.e., ivermectin). We found that adding this agent to the standard treatments for COVID-19 is ineffective or has no synergistic effect.

Please cite this paper as: Baghbanian R, Savaie M, Soltani F, Rashidi M, Dargahi MalAmir M, Amiri F, Bakhtiari N. The effect of adding ivermectin to the standard COVID-19 treatment in intubated patients. J Nephropharmacol. 2023;12(2):e10589. DOI: 10.34172/npj.2023.10589.

First Name
Last Name
Email Address
Security code

Abstract View: 1172

Your browser does not support the canvas element.

PDF Download: 526

Your browser does not support the canvas element.